Combination of anti-PD-1 treatment with chemotherapy in a patient with metaplastic breast cancer during lactation

Metaplastic breast cancer (MpBC) is a rare and aggressive subtype of breast cancer with a poor prognosis. Recent studies have shown that anti-PD-1 therapy is effective in treating this type of cancer. We described a rare case of MpBC during lactation that worsened quickly post-surgery. Despite receiving chemotherapy and immunotherapy, the patient passed away from respiratory failure caused by tumor compression. Subsequent genetic testing revealed the presence of the resistance gene CDKN2A. Lactating women should promptly get checked for abnormal breast symptoms to catch breast cancer early. More research is needed to determine how effective anti-PD-1 therapy is for MpBC. PD-L1 is not usually tested in clinical settings, but it's important to check for CDKN2A when looking at resistance targets for PD-L1.

Authors

Institutions

Publication Details

Journal
Immunotherapy
Published
2026-01-02
DOI
https://doi.org/10.1080/1750743x.2026.2623783
Primary Topic
Cancer Risks and Factors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Combination of anti-PD-1 treatment with chemotherapy in a patient with metaplastic breast cancer during lactation

Qinghong Yu, Hongting Wu, Xiufei Gao, Ying Jin et al.
Immunotherapy
Cancer Risks and Factors
article

Combination of anti-PD-1 treatment with chemotherapy in a patient with metaplastic breast cancer during lactation

Qinghong Yu, Hongting Wu, Xiufei Gao, Ying Jin, Jiaqing Song
article en

Abstract

Metaplastic breast cancer (MpBC) is a rare and aggressive subtype of breast cancer with a poor prognosis. Recent studies have shown that anti-PD-1 therapy is effective in treating this type of cancer. We described a rare case of MpBC during lactation that worsened quickly post-surgery. Despite receiving chemotherapy and immunotherapy, the patient passed away from respiratory failure caused by tumor compression. Subsequent genetic testing revealed the presence of the resistance gene CDKN2A. Lactating women should promptly get checked for abnormal breast symptoms to catch breast cancer early. More research is needed to determine how effective anti-PD-1 therapy is for MpBC. PD-L1 is not usually tested in clinical settings, but it's important to check for CDKN2A when looking at resistance targets for PD-L1.

ImmunotherapyVol. 18(1)
Zhejiang Chinese Medical University (CN), Shanghai University of Traditional Chinese Medicine (CN)
Good health and well-being
Openalex Percentile: Top 68%
Cancer Risks and Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Combination of anti-PD-1 treatment with chemotherapy in a patient with metaplastic breast cancer during lactation — Qinghong Yu, Hongting Wu, et al. · Immunotherapy (2026) | TGRS Research Map | TGRS